These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 23589033)

  • 21. 4G/5G polymorphism of PAI-1 gene promoter and fibrinolytic capacity in patients with deep vein thrombosis.
    Sartori MT; Wiman B; Vettore S; Dazzi F; Girolami A; Patrassi GM
    Thromb Haemost; 1998 Dec; 80(6):956-60. PubMed ID: 9869167
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasminogen activator inhibitor I 4G/5G polymorphism in neonatal respiratory distress syndrome.
    Armangil D; Yurdakök M; Okur H; Gürgey A
    Clin Appl Thromb Hemost; 2011 Aug; 17(4):352-7. PubMed ID: 20460339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Association of genetic polymorphisms in plasminogen activator inhibitor-1 gene and 5,10-methylenetetrahydrofolate reductase gene with recurrent early spontaneous abortion].
    Guan LX; Du XY; Wang JX; Gao L; Wang RL; Li HB; Wang SX
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2005 Jun; 22(3):330-3. PubMed ID: 15952129
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group.
    Hermans PW; Hibberd ML; Booy R; Daramola O; Hazelzet JA; de Groot R; Levin M
    Lancet; 1999 Aug; 354(9178):556-60. PubMed ID: 10470700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A study of the possible association of plasminogen activator inhibitor type 1 4G/5G insertion/deletion polymorphism with susceptibility to schizophrenia and in its subtypes.
    Yenilmez C; Ozdemir Koroglu Z; Kurt H; Yanas M; Colak E; Degirmenci I; Gunes HV
    J Clin Pharm Ther; 2017 Feb; 42(1):103-107. PubMed ID: 27796029
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Plasminogen activator inhibitor type 1 gene polymorphism and thromboses in patients with antiphospholipid syndrome].
    Reshetniak TM; Ostriakova EV; Patrusheva NL; Patrushev LI; Aleksandrova EN; Seredavkina NV; Volkov AV; Nasonov EL
    Ter Arkh; 2013; 85(1):76-84. PubMed ID: 23536951
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasminogen activator inhibitor-1 (PAI-1) antigen plasma levels in subjects attending a metabolic ward: relation to polymorphisms of PAI-1 and angiontensin converting enzyme (ACE) genes.
    Margaglione M; Grandone E; Vecchione G; Cappucci G; Giuliani N; Colaizzo D; Celentano E; Panico S; Di Minno G
    Arterioscler Thromb Vasc Biol; 1997 Oct; 17(10):2082-7. PubMed ID: 9351375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between PAI-1 polymorphisms and plasma PAI-1 level with sepsis in severely burned patients.
    Chi YF; Chai JK; Yu YM; Luo HM; Zhang QX; Feng R
    Genet Mol Res; 2015 Aug; 14(3):10081-6. PubMed ID: 26345945
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism.
    Stegnar M; Uhrin P; Peternel P; Mavri A; Salobir-Pajnic B; Stare J; Binder BR
    Thromb Haemost; 1998 May; 79(5):975-9. PubMed ID: 9609232
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The study of PAI-1 promotor region gene polymorphism in cerebrovascular disease].
    Zhang C; Li J; Li L; Luo B
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2001 Oct; 18(5):383-7. PubMed ID: 11592048
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Investigation of Plasminogen Activator Inhibitor-1 (PAI-1) 4G/5G promoter polymorphism in Indian venous thrombosis patients: A case-control study.
    Prabhudesai A; Shetty S; Ghosh K; Kulkarni B
    Eur J Haematol; 2017 Sep; 99(3):249-254. PubMed ID: 28561456
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Plasminogen activator inhibitor-1 (PAI-1) 4G/5G and angiotensin converting enzyme (ACE) I/D gene polymorphisms and fibrinolytic activity in patients with essential hypertension and dyslipidemia].
    Jastrzebska M; Widecka K; Ciechanowicz A; Goracy I; Wesołowska T; Torbus-Lisiecka B; Foltyńska-Nowakowska A; Naruszewicz M
    Pol Arch Med Wewn; 2005 Jan; 113(1):7-20. PubMed ID: 16130596
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Relationship between plasminogen activator inhibitor-1 gene 4G/5G polymorphism and type 2 diabetic nephropathy in Chinese Han patients in Guangdong Province].
    Liu SQ; Xue YM; Yang GC; He FY; Zhao XS
    Di Yi Jun Yi Da Xue Xue Bao; 2004 Aug; 24(8):904-7. PubMed ID: 15321757
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels.
    Diamanti-Kandarakis E; Palioniko G; Alexandraki K; Bergiele A; Koutsouba T; Bartzis M
    Eur J Endocrinol; 2004 Jun; 150(6):793-8. PubMed ID: 15191349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel G/A and the 4G/5G polymorphism within the promoter of the plasminogen activator inhibitor-1 gene in patients with deep vein thrombosis.
    Grubic N; Stegnar M; Peternel P; Kaider A; Binder BR
    Thromb Res; 1996 Dec; 84(6):431-43. PubMed ID: 8987164
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genotype frequency of plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism in healthy Japanese males and its relation to PAI-1 levels.
    Matsubara Y; Murata M; Isshiki I; Watanabe R; Zama T; Watanabe G; Watanabe K; Ikeda Y
    Int J Hematol; 1999 Jan; 69(1):43-7. PubMed ID: 10641442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasminogen activator inhibitor type-1 (PAI-1) polymorphism 4G/5G is associated with prostate cancer among men with a positive family history.
    Jorgenson E; Deitcher SR; Cicek M; Liu X; Plummer S; Casey G; Witte JS
    Prostate; 2007 Feb; 67(2):172-7. PubMed ID: 17044080
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduced carriership of 4G allele of plasminogen activator inhibitor-1 4G/5G polymorphism in very young survivors of myocardial infarction.
    Rallidis LS; Gialeraki A; Merkouri E; Liakos G; Dagres N; Sionis D; Travlou A; Lekakis J; Kremastinos DT
    J Thromb Thrombolysis; 2010 May; 29(4):497-502. PubMed ID: 19844663
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of stroke: replicated findings in two nested case-control studies based on independent cohorts.
    Wiklund PG; Nilsson L; Ardnor SN; Eriksson P; Johansson L; Stegmayr B; Hamsten A; Holmberg D; Asplund K
    Stroke; 2005 Aug; 36(8):1661-5. PubMed ID: 16020771
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diabetic retinopathy, promoter (4G/5G) polymorphism of PAI-1 gene, and PAI-1 activity in Pima Indians with type 2 diabetes.
    Nagi DK; McCormack LJ; Mohamed-Ali V; Yudkin JS; Knowler WC; Grant PJ
    Diabetes Care; 1997 Aug; 20(8):1304-9. PubMed ID: 9250459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.